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ABSTRACT
Introduction. In patients with potentially resectable
esophageal cancer (EC), the value of endoscopic ultra-
sonography (EUS) after fluorine-18 labeled fluorodeoxyglu-
cose positron emission tomography with computed tomog-
raphy (18F-FDG-PET/CT) is questionable. Retrospectively,
we assessed the impact of EUS after PET/CT on the given
treatment in EC patients.
Methods. During the period 2009–2015, 318 EC patients
were staged as T1-4aN0-3M0 with hybrid 18F-FDG-PET/
CT or 18F-FDG-PET with CT and EUS if applicable in a
nonspecific order. We determined the impact of EUS on
the given treatment in 279 patients who also were staged
with EUS. EUS had clinical consequences if it changed
curability, extent of radiation fields or lymph node resec-
tion (AJCC stations 2–5), and when the performed fine-
needle aspiration (FNA) provided conclusive information
of suspicious lymph node.
Results. EUS had an impact in 80 (28.7%) patients; it
changed the radiation field in 63 (22.6%), curability in 5
(1.8%), lymphadenectomy in 48 (17.2%), and FNA was
additional in 21 (7.5%). In patients treated with nCRT
(n = 194), EUS influenced treatment in 53 (27.3%)
patients; in 38 (19.6%) the radiation field changed, in 3
(1.5%) the curability, in 35 (18.0%) the lymphadenectomy,
and in 17 (8.8%) FNA was additional. EUS influenced both
the extent of radiation field and nodal resection in 31
(16.0%) nCRT patients.
Conclusions. EUS had an impact on the given treatment in
approximately 29%. In most patients, the magnitude of
EUS found expression in the extent of radiotherapy target
volume delineation to upper/high mediastinal lymph nodes.
Accurate staging is essential for oncological outcome in
patients with potentially curable esophageal cancer for
determining the optimal treatment approach and adequate
target volume delineation (gross tumor volume of primary
tumor and malignant nodes and hence clinical target vol-
ume) when radiotherapy is indicated. Fluorine-18 labeled
fluorodeoxyglucose positron emission tomography with
computed tomography (18F-FDG-PET/CT) is currently the
best method to detect distant metastases, whereas endo-
scopic ultrasonography (EUS) with or without fine-needle
aspiration (FNA) is the method of choice to determine the
extent and depth-growth of the primary tumor (T-stage)
and detection of lymph node metastases (N-stage).1–3
Contradictory results have been reported regarding the
additional role of EUS after 18F-FDG-PET, 18F-FDG-PET/
CT or CT alone.4–8 Mortensen et al. found that EUS
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influenced treatment decisions in 34% of the EC patients
after CT alone, whereas Findlay et al. found that the risks
outweighed the potential benefit of EUS in patients with
T2-4a disease on CT.4,5 Some studies showed upfront 18F-
FDG-PET followed by EUS as the best predictor of cura-
tive resectability and the most cost-effective staging
sequence.7,8 However, most studies determined the influ-
ence of EUS with questionnaires completed by involved
medical specialists and not with the clinical impact or
diagnostic position of EUS after 18F-FDG-PET/CT.4,6
Moreover, these studies did not assess the magnitude of
EUS on radiotherapy target volume delineation; nowadays
most patients receive radiotherapy in a combined curative
treatment approach.
In addition, EUS has several limitations, including the
invasive character of the procedure with risk of aspiration,
perforation, and bleeding, whereas tumor stenosis, which
occurs between 20 and 36% of the patients, limits its
clinical usage.3,9–11 Precluding unnecessary EUS is there-
fore patient-friendly in case of a strong suspicion of distant
metastases or in case of localized disease on 18F-FDG-
PET/CT and reduces the risks of complications and even-
tually costs.
With 18F-FDG-PET/CT upfront staging sequence,
unnecessary primary endoscopic procedures may be pre-
vented, by 18F-FDG-PET/CT guiding of concurrent EUS
with fine needle aspiration (FNA) of pathological
(non)regional lymph nodes.
The purpose of this study was to determine the clinical
impact of EUS after upfront 18F-FDG-PET/CT staging on
the given treatment, by determining if EUS had changed
radiotherapy target volume delineation, curability, extent of
lymph node resection, and whether FNA was of additive
value. We also investigated the additional value of EUS on
nodal up/downstaging, on the number of lymph nodes sus-
pected for metastasis, and station-specific nodal (N) status.
PATIENTS AND METHODS
A total of 318 patients were included in this retrospec-
tive study, which was performed according to the
guidelines of the local Ethical Boards and national rules for
retrospective studies. All esophageal cancer patients
(n = 388) scheduled for an in onset curative intended
treatment (T1-4aN0-3M0), diagnosed at the University
Medical Center Groningen (UMCG) or Medical Center
Leeuwarden between 2009 and 2015, were eligible for
inclusion. All consecutive patients had a pathologically
proven adeno- or squamous cell carcinoma, located in the
mid or distal esophagus or at the gastroesophageal junction.
Excluded were patients treated with endoscopic mucosal
resection before (n = 7) or after (n = 3) staging, without
18F-FDG-PET or 18F-FDG-PET/CT scanning (n = 17),
without a visible tumor on 18F-FDG-PET/CT (n = 15), or
with missing staging data (n = 28).
Methods
First, we determined the number of patients who had a
complete or incomplete EUS and those without EUS. To
answer the primary research question, all patients with a
complete or incomplete EUS were selected. We then asses-
sed if EUS had an impact on the given treatment. Compared
with the noninvasive 18F-FDG-PET/CT, EUS had influenced
the given treatment if: EUS changed the extent of radiation
target volumes (smaller, larger, or both), changed the cur-
ability (from incurable based on 18F-FDG-PET/CT to
potentially curable), influenced the extent of lymph node
dissection (i.e., changed suspicion for lymph node metastasis
at AJCC lymph node stations 2–5), or/and when the per-
formed fine-needle aspiration (FNA) provided conclusive
information of suspicious lymph node.12 Thereafter, we
assessed the clinical impact of EUS on the given treatment in
the total patient group (all treatments with curative intent),
followed by the neoadjuvant chemoradiotherapy (nCRT),
the surgery-alone, and a combined (chemoradiotherapy and
definitive radiotherapy (dCRT/dRT) group.
The researchers (JBH & VEMM) assessed the radio-
therapy tumor volume (TV) delineations and determined if
the EUS findings had changed the radiotherapy target
volumes. EUS enlarged the radiotherapy target volume
delineation if EUS-FNA had identified new lymph node
suspicious for metastases that were located outside of the
clinical target volume (CTV: treatment section) based on
the 18F-FDG-PET/CT. Lymph nodes were scored by size,
shape, echoic pattern, and sharpness of the border. EUS
decreased the radiotherapy target volume delineation if
initially suspected lymph nodes on the 18F-FDG-PET/CT,
located outside of the CTV, were reassessed as negative
based on EUS findings and/or confirmed cytologically as
FNA-negative. Secondary outcomes included the number
of patients with an altered N-stage, with a difference in the
number of lymph nodes suspected for metastases, and
changes in the localization of suspected lymph nodes.
Staging
Patients were staged according to the 7th TNM classi-
fication of the American Joint Committee on Cancer
(AJCC) with diagnostic gastroscopy and biopsy, a diag-
nostic CT thorax/abdomen, 18F-FDG-PET or 18F-FDG-
PET/CT, and EUS if possible.13 Depending on the tumor-
specific situation, EUS was performed with either a high-
frequency (12–20 MHz) linear or radial probes. Esopha-
geal dilatation was not performed routinely in patients with
stenosis. The results of all staging methods were discussed
J. B. Hulshoff et al.
in a multidisciplinary tumor board. Abnormalities and non-
regional lesions relatively suspect for being a distant
metastasis were either proven pathologically under imag-
ing guided biopsies or assessed with additional imaging
techniques i.e., magnetic resonance imaging (MRI) or
endobronchial ultrasound/FNA.
Treatment
nCRT followed by surgery consisted of carboplatin and
paclitaxel according to the CROSS regimen combined with
radiotherapy (41.4 Gy/23 fractions).14 dCRT consisted of
either carboplatin/paclitaxel or cisplatin and fluorouracil
(Cis-5FU) combined with radiotherapy (50.4 Gy).15 dRT
commonly consisted of 60 Gy in 30 fractions.
In all patients who received external beam radiotherapy,
the gross tumor volume (GTV) was delineated on a plan-
ning CT scan, using all additional staging information. The
GTV contained both the primary tumor and adjacent lymph
nodes. The clinical target volume (CTV) is a margin of
3–3.5 cm in cranial and caudal direction and 1–2 cm
transversally. The CTV was adjusted to normal tissue.
Suspicious lymph nodes located outside the CTV were
radiated separately with 1-cm margin.
Surgery consisted of either a transthoracic, transhiatal,
or minimally invasive radical esophagectomy with a two-
field lymph node dissection and was normally performed
6–10 weeks after the end of nCRT.
Statistical Analysis
All data were displayed as numbers (percentages).
Normally distributed data were displayed as mean (stan-
dard deviation). Nonnormally distributed data were
displayed as median [interquartile range (IQR)]. Differ-
ences in categorical variables were assessed using logistic
regression, Chi square test, or likelihood ratio. All data
were analyzed using SPSS statistical software, version 22
(SPSS Inc., Chicago, IL).
RESULTS
Table 1 displays the patients’ characteristics, tumor-re-
lated, and treatment-related data of the 318 included
patients. Of these patients, 250 (78.6%) had an adenocar-
cinoma and 68 (21.4%) had a squamous cell carcinoma.
The localization of the primary tumor was generally in the
distal esophagus (n = 221: 69.5%), followed by the gas-
troesophageal junction (n = 52: 16.4%), and mid
esophagus (n = 45: 14.2%). Most patients were treated
with curative intent with surgery after nCRT (n = 212:
66.7%), followed by surgery-alone (n = 50: 15.7%), dCRT
(n = 29: 9.1%), and dRT (n = 27: 8.5%).
Table 2 displays the endoscopic ultrasonography-related
data. EUS was not performed in 39 (12.3%) patients
because of stenosis (n = 30/9.4%), patient related reasons
(n = 4), and for unknown reasons (n = 5). In total, EUS
could be performed in 279 patients: 200 (62.9%) had a
complete and 79 (24.8%) an incomplete EUS, because of
stenosis (n = 78/24.5%) and patients related reason
(n = 1).
Influence of EUS on the Given Treatment
Table 3 displays the additional information that EUS
provided compared with upfront 18F-FDG-PET/CT. EUS
had influenced the primary treatment in 80 (28.7%)
patients. In most patients (n = 63: 22.6%), EUS influenced
the extent of radiation target volumes: by increasing the
radiotherapy target volume delineation in 45 (16.1%)
patients, decreasing these delineation in 17 (6.1%), and
both extending and decreasing the target volume in 1
(0.4%) patient. EUS had changed the curability (incurable
to potentially curable) in 5 (1.8%) patients, influenced the
extent of LN resection (at node level AJCC Lymph node
stations 2–5) in 48 (17.2%), and affected treatment deci-
sion-making with FNA in 21 patients (7.5%).
Thereafter, we found that histologic tumor type did not
influence the effect of EUS on the given treatment
(P = 0.614). The location of the primary tumor also
influenced the effect of EUS on the given treatment
(P = 0.043): midesophageal-located cancers interfered
with the treatment in 16 (47.1%), distal EC in 50 (25.3%),
and gastroesophageal junction tumors in 14 (29.8%)
patients.
In the nCRT group (n = 194), EUS changed the pro-
posed treatment based on upfront 18F-FDG-PET-CT in 53
(27.3%). In 52 (26.8%) patients, it influenced the radiation
target volumes, in 3 (1.5%) the curability, in 35 (18.0%)
the extent of lymph node dissection, and in 17 (8.8%) FNA
added valuable information. Of all patients, in 31 (16.0%)
EUS affected the extent of both, the radiation target vol-
umes and the lymph node dissection, usually at AJCC
lymph node 2–5, implicating EUS to be valuable in iden-
tifying mediastinal lymph node metastases, especially these
upper/high lymph nodes.
EUS influenced the treatment in 13 (28.9%) surgery-
alone treated patients (n = 45), all by extending the lymph
node dissection: EUS identified mediastinal/high lymph
node metastasis in 9 (20.0%) patients with 18F-FDG-PET/
CT positive lymph nodes, whereas in 4 (8.9%) other
patients the 18F-FDG-PET/CT positive lymph nodes turned
out to be negative on EUS. In 3 (6.7%) of these 13 patients,
FNA was performed and conclusive.
EUS influenced the treatment in 14 (35.0%) patients
treated with dCRT or dRT: in 11 (27.5%) it changed the
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radiation target volumes, in 2 (5.0%) the curability, and in
1 (2.5%) patient FNA was additional. In most of these
patients EUS enlarged the radiation target volumes 7
(17.5%), while it was decreased in 4 (10.0%) patients.
Additional Value of EUS
Additional lymph nodes were detected in 150 (53.8%)
patients, whereas less suspicious lymph nodes were found
in 32 (11.5%). EUS caused N upstaging in 107 (38.4%) and
N downstaging in 31 (11.1%) patients. In 77 (27.6%)
patients, EUS found suspicious lymph nodes at other nodal
stations than with 18F-FDG-PET/CT. In total, 7 (2.5%)
patients received a re-EUS examination after primary EUS,
because of suspect lymph nodes on the 18F-FDG-PET or
CT (n = 3), an unclear outcome of the FNA (n = 3), or an
unclear outcome of the EUS itself (n = 1).
DISCUSSION
Accurate staging is of vital importance in the treatment
decision-making process and radiotherapy target volume
delineation and hence the adjusted correct treatment. The
value of EUS after an upfront 18F-FDG-PET/CT scan
remains matter or debate. Staging with EUS seems
TABLE 1 Patient, tumor, and treatment characteristics
All patients (n = 318), n (%) Patients with a complete EUS (n = 279), n (%)
Male 248 (78.0%) 216 (77.4%)
Age (year); median (IQR) 65 (59–70) 65 (60–70)
Histology
Adenocarcinoma 250 (78.6%) 225 (80.6%)
Squamous cell carcinoma 68 (21.4%) 54 (19.4%)
Tumor location
Middle esophagus 45 (14.2%) 34 (12.2%)
Distal esophagus 221 (69.5%) 198 (71.0%)
GEJ 52 (16.4%) 47 (16.8%)
Tumor length (cm); median (IQR) 5.0 (3.0-7.0) 5.0 (3.0-6.0)
cT-stage
T1 11 (3.5%) 10 (3.6%)
T2 41 (12.9%) 39 (14.0%)
T3 243 (76.4%) 218 (78.1%)
T4a 23 (7.2%) 12 (4.3%)
cN-stage
N0 85 (26.7%) 70 (25.1%)
N1 117 (36.8%) 100 (35.8%)
N2 99 (31.1%) 93 (33.3%)
N3 15 (4.7%) 15 (5.4%)
Missing 2 (0.6%) 1 (0.4%)
Treatment
Surgery-alone 50 (15.7%) 45 (16.1%)
nCRT 212 (66.7%) 194 (69.5%)
dCRT 29 (9.1%) 21 (7.5%)
dRT 27 (8.5%) 19 (6.8%)
IQR interquartile range, GEJ gastroesophageal junction, cT-stage clinical T-stage, cN-stage clinical N-stage, nCRT neoadjuvant chemoradio-
therapy, dCRT definitive chemoradiotherapy, dRT definitive radiotherapy
TABLE 2 Endoscopic ultrasonography-related data
All patients (n = 318), n (%)
EUS successful 200 (62.9%)
EUS incomplete 79 (24.8%)
Stenosis 78 (24.5%)
Patient-related 1 (0.3%)
EUS not performed 39 (12.3%)
Stenosis 30 (9.4%)
Patient related 4 (1.3%)
On indication no EUS 1 (0.3%)
Unknown 4 (1.3%)
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required, because it has the highest sensitivity and accuracy
in detecting lymph nodes suspicious for metastatic disease,
whereas high regional recurrence rates also suggested the
need for a more accurate radiotherapy delineation of
involved lymph node stations. In clinical practice, not all
patients benefit from EUS because of severe stenosis in
approximately 20–36%.11 The present study is the first to
determine the influence of EUS on the given treatment with
curative intent. We found that EUS influenced treatment in
approximately 29% of the patients. Moreover, EUS was
especially important for adequate delineation of radio-
therapy target volumes, implicating its importance in
locoregional control and treatment of esophageal cancer
patients with nCRT.
Several studies previously determined the influence of
EUS on treatment decision-making, but not on the given
treatment itself. Two studies determined the influence of
EUS after CT-alone, with a questionnaire, and found that
EUS changed the treatment decision in 24–34% of the
patients.4,6 A study by Van Zoonen determined that
TABLE 3 Influence of EUS compared to 18F-FDG-PET/CT
All patients (n = 279),
n (%)
nCRT (n = 194),
n (%)
Surgery-alone (n = 45),
n (%)




80 (28.7%) 53 (27.3%) 13 (28.9%) 14 (35.0%)
Radiotherapy fields 63 (22.6%) 52 (26.8%) n.a. 11 (27.5%)
Larger RT field 45 (16.1%) 38 (19.6%) n.a. 7 (17.5%)
Smaller RT field 17 (6.1%) 13 (6.7%) n.a. 4 (10.0%)
Smaller and larger 1 (0.4%) 1 (0.5%) n.a. 0 (0.0%)
Incurable ? curable 5 (1.8%) 3 (1.5%) 0 (0.0%) 2 (5.0%)
Influence on LN resection 48 (17.2%) 35 (18.0%) 13 (28.9%) n.a.
Positive on EUS 29 (10.4%) 20 (10.3%) 9 (20.0%) n.a.
Negative on EUS 19 (6.8%) 15 (7.7%) 4 (8.9%) n.a.
FNA additional 21 (7.5%) 17 (8.8%) 3 (6.7%) 1 (2.5%)
Fine-needle aspiration
Positive 22 (7.9%) 14 (7.2%) 1 (2.2%) 7 (17.5%)
Negative 31 (11.1%) 27 (13.9%) 4 (8.9%) 0 (0.0%)
Inconclusive 5 (1.8%) 2 (1.0%) 2 (4.4%) 1 (2.5%)
N up/down staging
up staging 107 (38.4%) 87 (44.8%) 12 (26.7%) 8 (20.0%)
down staging 31 (11.1%) 15 (7.7%) 9 (20.0%) 7 (17.5%)
More LN found with EUS 150 (53.8%) 113 (58.2%) 18 (40.0%) 19 (47.5%)
Less LN found with EUS 32 (11.5%) 16 (8.2%) 9 (20.0%) 7 (17.5%)
Other LN localization 77 (27.6%) 52 (26.8%) 11 (24.4%) 14 (35.0%)
Additional staging techniques
Bronchoscopy 8 (2.9%) 2 (1.0%) 0 (0.0%) 6 (15.0%)
EBUS 6 (2.2%) 4 (2.1%) 1 (2.2%) 1 (2.5%)
Ultrasound liver 11 (3.9%) 6 (3.1%) 4 (8.9%) 1 (2.5%)
Ultrasound neck 21 (7.5%) 16 (8.2%) 2 (4.4%) 3 (7.5%)
MRI liver 1 (0.4%) 1 (0.5%) 0 (0.0%) 0 (0.0%)
CT liver 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (2.5%)
CT thorax 2 (0.7%) 2 (1.0%) 0 (0.0%) 0 (0.0%)
CT brain 1 (0.4%) 1 (0.5%) 0 (0.0%) 0 (0.0%)
Mediastinoscopy 1 (0.4%) 0 (0.0%) 1 (2.2%) 0 (0.0%)
Number of EUS
1 272 (97.5%) 191 (98.5%) 45 (100%) 36 (90.0%)
2 7 (2.5%) 3 (1.5%) 0 (0.0%) 4 (10.0%)
nCRT neoadjuvant chemoradiotherapy, dCRT definitive chemoradiotherapy, dRT definitive radiotherapy, EUS endoscopic ultrasonography, RT
radiotherapy, LN lymph node, FNA fine-needle aspiration, EBUS endobronchial ultrasound, n.a. not applicable
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although EUS increased the specificity after CT and
ultrasound of the neck, the additional value on determining
the surgical resectability was limited.16 Moreover, Findlay
et al. found that the risk of EUS in T2-4a patients on CT
outweighed the additional information of EUS on T- and
N-stage.5 The only study that compared EUS with 18F-
FDG-PET/CT was the study by Schreurs et al., which
found that 18F-FDG-PET/CT was the best predictor of
curability of the resection.8 However, as mentioned, the
studies above only determined the influence of EUS on
treatment decision making and not on the given treatment
itself, whereas detection of metastatic lymph nodes located
at some distance of the primary tumor is of fast importance
for radiotherapy delineation in the era of nCRT. Currently,
the role of EUS in treatment decision making might be
limited: In the current treatment paradigm, treatment
decision making in T2-4aN0-3M0 esophageal cancer
patients is most commonly based on the presence of
comorbidities that might not permit nCRT or dCRT. As
mentioned, EUS is especially important in patients eligible
for nCRT, dCRT, or dRT. Refraining from EUS would
have caused inadequate radiotherapy target volumes in
approximately 19.6% of the nCRT and 17.5% of the dCRT
and dRT patients. In patients eligible for treatment with
dCRT and dRT group, this might lead to impaired
locoregional control of disease. On the other hand,
refraining from EUS would have caused an unnecessary
large radiotherapy target volumes in approximately 7% of
the patients treated with nCRT and 10% of the dCRT and
dRT, which could increase the risk of radiotherapy induced
toxicities.
In the future, diffusion-weighted magnetic resonance
imaging (DW-MRI) with contrast agents that are taken up
by lymph nodes, i.e., Gadofosveset or ultra-small iron
particles, might improve the detection of suspicious lymph
nodes.17 Moreover, in the coming years proton therapy will
become more clinically available, which will decrease the
radiation associated (cardiopulmonary) toxicities.18
An important limitation of this study is its retrospective
character, which sometimes impedes the exact anatomical
information about suspected lymph node metastases,
although all lymph node metastases were scored according
to the AJCC system by the researchers. The rate of FNA
procedures was rather low in present study (n = 58:
20.8%), which may have resulted in false-positive EUS
results and probably unnecessary upstaging, because the
accuracy of EUS for predicting lymph nodes on echo
features in different cancers is approximately 80%.19 A
large, prospective study with well-defined FNA of sus-
pected lymph nodes might determine the exact role of EUS
in up- and downstaging, although accurate EUS with FNA
is time-consuming and should be performed in centralized
institute because of its relative complexity. In improving
the detection of involved regions with potential harmless
imaging modalities, the recent use of DW-MRI seems to be
of great importance.
In conclusion, our study determined the additional value
of EUS on the given treatment and found that EUS was of
added value in approximately 29%. EUS seems especially
important for radiotherapy target volume delineation of
mediastinal and high mediastinal lymph nodes metastases,
implicating its importance in staging esophageal cancer
patients planned to be treated with curative intended nCRT.
Future, prospective studies with current sophisticated
imaging would determine the exact place of EUS-FNA in
EC staging.
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